Top Markets
Coin of the day
Bellicum Pharmaceuticals, Inc. Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc.

BLCM
Kedudukan dalam Saham #38884
Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage... Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.
Harga Saham
$0.07475
Disegerakkan terakhir: 2024-03-04
Modal Pasaran
$755.60K
Perubahan (1 hari)
-6.68%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Bellicum Pharmaceuticals, Inc. (BLCM)

Kategori

Hasil untuk Bellicum Pharmaceuticals, Inc. (BLCM)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Bellicum Pharmaceuticals, Inc., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Bellicum Pharmaceuticals, Inc. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE